Adventrx Halts Phase III Study Of CoFactor In Metastatic Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Further development of biomodulator depends heavily on results of a breast cancer study, expected in Q2 2008, CEO Levine says at BIOCOM Investor Conference.